Skip to main content

Table 1 Baseline characteristics of 1434 patients who underwent anti-TNF therapy

From: Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea

Characteristics  
Age of IBD diagnosis (years) 25.81 ± 12.45
Age at anti-TNF therapy initiation (years) 31.35 ± 13.59
Follow up (months) 48.54 ± 36.48
Sex (male:female) 940:494
IBD type (UC:CD) 332 (23.2%):1102 (76.8%)
History of smoking (no:yes) 991 (69.1%):443 (30.9%)
Anti-TNF agents  
 One 1259 (87.8%)
  Infliximab 939 (65.5%)
  Adalimumab 311 (21.7%)
  Golimumab 9 (0.6%)
 Two 172 (12.0%)
  Infliximab, Adalimumab 166 (11.6%)
  Infliximab, Golimumab 2 (0.1%)
  Adalimumab, Golimumab 4 (0.3%)
 Three 3 (0.2%)
LTBI diagnosis  
 Done 1333 (93.0%)
  Negative 1135 (85.1%)
  Positive 198 (14.9%)
   Completion of TB prophylaxis 190 (96%)
   Failure to complete TB prophylaxis 8 (4.0%)
 Not done, other 101 (7.0%)
  1. TNF, tumor necrosis factor; IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn’s disease; LTBI, latent tuberculosis infection; TB, tuberculosis